---
title: "Outro Health Raises $7M for Antidepressant Deprescribing Platform"
description: "New York-based Outro Health has secured $7 million in a funding round combining pre-seed and seed financing, according to multiple reports. The investor syndicate included Pave Health Ventures, Listen Ventures, Cake Ventures, Jason Calacanis's LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, and Brock Recovery Group, several outlets reported."
canonical_url: https://clinicalterminal.com/article/107521659
section: funding-and-ma
byline: Victoria Shi · AI Funding Reporter
date_published: 2026-10-21T03:20:15.483Z
date_label: October 21, 2026
image: https://firebasestorage.googleapis.com/v0/b/clinical-ai-design.firebasestorage.app/o/desk-heroes%2Ffe_MVzDRrTFKNIugbXXUnTW%2Fhero_a5578fda8a1e_w1920.jpg?alt=media
source: https://clinicalterminal.com
---

# Outro Health Raises $7M for Antidepressant Deprescribing Platform

*New York-based [Outro Health](https://app.clinicalterminal.com/company/107515193) has secured $7 million in a funding round combining pre-seed and seed financing, according to multiple reports. The investor syndicate included [Pave Health Ventures](https://app.clinicalterminal.com/company/106653408), Listen Ventures, Cake Ventures, Jason Calacanis's LAUNCH, [Actions Capital](https://app.clinicalterminal.com/company/100348124), [Hannah Grey VC](https://app.clinicalterminal.com/company/107515195), [SemperVirens](https://app.clinicalterminal.com/company/107515196), and [Brock Recovery Group](https://app.clinicalterminal.com/company/107515197), several outlets reported.*

Outro Health operates a virtual clinic platform to help patients safely stop taking psychiatric medications, with an initial focus on antidepressants, according to MobiHealthNews and other reports. The company provides patients with access to clinicians who create personalized tapering plans and offers ongoing monitoring and psychosocial support. Its Taper Management program is currently available in 14 U.S. states, HIT Consultant reported.

Outro Health plans to use the capital to expand its network of clinicians, integrate artificial intelligence into its clinical workflows, and extend its services to cover other classes of medication, according to news outlets. The funding will also support partnerships with universities and patient advocacy organizations, MobiHealthNews and Dealroom.co reported.

In a LinkedIn post, Pave partner [Jacob Ritter Myers](https://app.clinicalterminal.com/person/106653798) commented on the investment, stating that Pave's work “centers on one idea: healthcare is being rebuilt to better serve people, and the next generation of health companies will be built around what patients actually want, not around what keeps them in the system.”

Clinical Terminal does not have a vendor profile for Pave Health Ventures.

## Sources

- [LinkedIn post by Jacob Ritter Myers](https://www.linkedin.com/posts/jacob-ritter-myers-1353b142_its-easier-than-ever-to-start-a-drug-it-activity-7514074605679214592-YZRL)
- [hlth.com](https://hlth.com/insights/news/outro-secures-7-million-to-expand-antidepressant-deprescribing-services)
- [mobihealthnews.com](https://www.mobihealthnews.com/news/outro-raises-7m-antidepressant-tapering)
- [hitconsultant.net](https://hitconsultant.net/2026/10/12/outro-raises-7m-neuroscience-deprescribing-platform-antidepressant-tapering/)
- Clinical Terminal vendor profiles

---
Canonical article: https://clinicalterminal.com/article/107521659  
Entity profiles referenced above resolve to https://app.clinicalterminal.com.